A fixed 'single vial' dose of subcutaneous desmopressin (DDAVP) produces adequate biologic responses for persons with mild haemophilia A

Haemophilia. 2021 Jul;27(4):e540-e542. doi: 10.1111/hae.14287. Epub 2021 Mar 8.

Authors

Joseph Noye^{1

2}, John A Rowell¹, Beryl Zeissink¹, Alex Connolly¹, Jane A Mason^{1

2

3}

Affiliations

¹ Queensland Haemophilia Centre, Department of Haematology and Cancer Care, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
² School of Clinical Medicine, University of Queensland, Brisbane, Queensland, Australia.
³ Australian Haemophilia Centre Directors Organisation (AHCDO), Melbourne, Victoria, Australia.

PMID: 33684234
DOI: 10.1111/hae.14287

No abstract available

Keywords: Octostim; desmopressin; haemophilia A; haemostasis; subcutaneous; treatment.

Publication types

Letter

MeSH terms

Biological Products*
Deamino Arginine Vasopressin
Factor VIII
Hemophilia A* / drug therapy
Humans
von Willebrand Diseases*

Substances

Biological Products
Factor VIII
Deamino Arginine Vasopressin